https://pittplusme.org/study/1630
HCC 19-039: Advanced HER2-Negative Breast Cancer
STUDY BASICS
Do you have advanced HER2-negative breast cancer that has progressed or returned after treatment? You may be able to participate in a research study to find out if the combination of balixafortide and eribulin is a safe and effective treatment for women with advanced HER2-negative breast cancer.
STUDY PURPOSE
Advanced HER2-negative breast cancer that has grown in size, spread to other parts of the body, or reoccurred after treatment can be difficult to treat. The purpose of this study is to find out if the combination of balixafortide and eribulin is a safe and effective treatment for people with advanced HER2-negative breast cancer who have received prior treatment. Eribulin is a standard chemotherapy drug used to treat advanced breast cancer. Balixafortide is an experimental (not FDA-approved) drug that may enhance the effects of chemotherapy.
COULD THIS STUDY BE RIGHT FOR YOU?
- Diagnosed with HER2-negative breast cancer that has progressed or returned after treatment
- Have already received at least 1 treatment for your breast cancer
WHAT PARTICIPANTS CAN EXPECT
Participation includes an initial visit to find out if you are eligible for the study. Eligible participants will be randomly assigned (like the flip of a coin) to receive either balixafortide plus eribulin or eribulin alone. Both study drugs are given by injection into one of your veins.
Tests and assessments during the study may include blood and urine collection, physical exam, electrocardiogram, and CT/MRI scans.
Patricipants will be reimbursed $75 for each completed study visit.
IRB: SSU00087161
- Polyphor Ltd. – POL6326-009, An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer (Pro00031569)
MEET THE RESEARCHER
Adam Brufsky
Adam M. Brufsky, MD, PhD, is Associate Chief and Professor of Medicine in the Division of Hematology/Oncology in the Department of Medicine at the University of Pittsburgh and Associate Director of Clinical Investigation for the University of Pittsburgh Cancer Institute. Dr. Brufsky received his medical degree and doctorate from the University of Connecticut School of Medicine. He completed his residency in internal medicine at Brigham and Women's Hospital, Harvard Medical School and a fellowship in medical oncology and bone marrow transplantation at the Dana-Farber Cancer Institute. Dr. Brufsky’s research interests include novel therapies for breast cancer, bone-breast cancer interactions and therapeutics, and the molecular biology of metastatic breast cancer.